New World Medical has received 510(k) clearance from the US Food and Drug Administration (FDA) for its VIA360 Surgical System, for the delivery of controlled amounts of viscoelas­tic fluid during ophthalmic surgeries. The VIA360, which is also indicated to cut trabecular meshwork tissue during trabeculotomy procedures, supports a variety of surgical workflows, whether combined with cataract surgery or in standalone procedures, the company said in a press release. 

According to New World Medical, the VIA360 Surgical System's proprietary ActiveInject Technology enables on-demand viscoelastic delivery independent of catheter movement, and its Smart Prime System optimizes viscoelastic volume ensuring efficiency throughout the procedure. The device's microcatheter is designed to advance up to 360° with microchannels configured to deliver viscoelastic both forward and tangentially ensuring the delivery of ophthalmic viscoelastic fluid to targeted areas. In addition, the technology's rotatable cannula provides enhanced positioning and flexibility for a single entry without requiring full device rotation.

The company reports that it will launch the VIA360 Surgical System in the US market immediately.